The introduction of PET/CT with more specific tracers for prostate cancer (Choline, Fluciclovine and PSMA) led to a metastasis-directed therapy (MDT) approach, to delay systemic therapy [8,10,11]. The gene discussed is FOLH1; the disease is prostate carcinoma.